by admin | Nov 14, 2023 | press-releases
Home PRESS RELEASE CG Oncology Announces Presentation of the First Phase 3 Monotherapy Data for Cretostimogene Grenadenorepvec in BCG-Unresponsive NMIBC Patients at SUO 2023 π» DESKTOP AUDIO PLAYER =============================== --> Listen to this article now 0:00 π±...
by admin | Sep 5, 2023 | press-releases
Home PRESS RELEASE CG Oncology Announces Key Executive Appointments in Commercialization, Medical and Manufacturing Operations π» DESKTOP AUDIO PLAYER =============================== --> Listen to this article now 0:00 π± MOBILE AUDIO PLAYER...
by admin | Aug 2, 2023 | press-releases
Home PRESS RELEASE CG Oncology Announces $105 Million Oversubscribed Crossover Financing to Support Continued Advancement of Clinical-Stage Bladder Cancer Pipeline π» DESKTOP AUDIO PLAYER =============================== --> Listen to this article now 0:00 π± MOBILE...
by admin | Jul 24, 2023 | press-releases
Home PRESS RELEASE CG Oncology Completes Patient Enrollment in BOND-003 Phase 3 Monotherapy Study with cretostimogene grenadenorepvec in BCG-Unresponsive High-Risk NMIBC π» DESKTOP AUDIO PLAYER =============================== --> Listen to this article now 0:00 π±...
by admin | May 3, 2023 | press-releases
Home PRESS RELEASE CG Oncology Announces New Phase 2 Data with cretostimogene grenadenorepvec in Combination with pembrolizumab in BCG-Unresponsive NMIBC π» DESKTOP AUDIO PLAYER =============================== --> Listen to this article now 0:00 π± MOBILE AUDIO PLAYER...
by admin | Apr 10, 2023 | press-releases
Home PRESS RELEASE New Phase 2 Data with cretostimogene grenadenorepvec in Combination with pembrolizumab in BCG-Unresponsive NMIBC at the AUA 2023 Annual Meeting π» DESKTOP AUDIO PLAYER =============================== --> Listen to this article now 0:00 π± MOBILE AUDIO...